Tarsheen Sethi, MD, MSCI
Assistant Professor of Medicine (Hematology)
Research & Publications
Biography
Research Summary
Her research is aimed at improving care and outcomes of Hodgkin and Non-Hodgkin lymphoma patients. She is also interested in studying the applications of tumor immunology and immunotherapy to hematologic malignancies focusing on lymphoma.
Extensive Research Description
Her research is aimed at improving care and outcomes of Hodgkin and Non-Hodgkin lymphoma patients. She is also interested in studying the applications of tumor immunology and immunotherapy to hematologic malignancies focusing on lymphoma.
Coauthors
Research Interests
Hodgkin Disease; Lymphoma
Selected Publications
- Chemotherapy Knowledge Base Management in the Era of Precision Oncology.Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR, Yang PC, Warner JL. Chemotherapy Knowledge Base Management in the Era of Precision Oncology. JCO Clinical Cancer Informatics 2021, 5: 30-35. PMID: 33411619, PMCID: PMC8189622, DOI: 10.1200/CCI.20.00076.
- How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.
- Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside.Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal Of Leukocyte Biology 2020, 108: 1455-1489. PMID: 32557857, DOI: 10.1002/JLB.5BT0420-585RR.
- Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies.Sethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2019, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.
- Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Ann Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.
- Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation.Aghighi M, Theruvath AJ, Pareek A, Pisani LL, Alford R, Muehe AM, Sethi TK, Holdsworth SJ, Hazard FK, Gratzinger D, Luna-Fineman S, Advani R, Spunt SL, Daldrup-Link HE. Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 4110-4118. PMID: 29764855, PMCID: PMC6125171, DOI: 10.1158/1078-0432.CCR-18-0673.
- Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma.Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2017, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.
- Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y.
- Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 2017, 23: 1473-1477. PMID: 28546074, DOI: 10.1016/j.bbmt.2017.05.020.
- Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology 2016, 280: 905-15. PMID: 26982677, PMCID: PMC5006736, DOI: 10.1148/radiol.2016151301.
- Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.Sethi TK, Keedy VL. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas. Current Treatment Options In Oncology 2016, 17: 11. PMID: 26931561, DOI: 10.1007/s11864-015-0382-0.
- Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma.Reddy NM, Sethi TK. Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma. The Lancet. Oncology 2016, 17: 1176-7. PMID: 27470080, DOI: 10.1016/S1470-2045(16)30205-4.
- Radon and lung cancer.Sethi TK, El-Ghamry MN, Kloecker GH. Radon and lung cancer. Clinical Advances In Hematology & Oncology : H&O 2012, 10: 157-64. PMID: 22402423.
- Iron deficiency masquerading as idiopathic intracranial hypertension.Kaul B, Ramanarayanan S, Mahapatra H, Sethi TK, Ahlawat R. Iron deficiency masquerading as idiopathic intracranial hypertension. BMJ Case Reports 2009, 2009 PMID: 21686848, PMCID: PMC3028304, DOI: 10.1136/bcr.06.2008.0346.